文献速递新生儿儿童内分泌与遗传代谢

葡萄糖凝胶治疗新生儿低血糖的成本分析

Cost Analysis of Treating Neonatal Hypoglycemia with Dextrose Gel.
PubMed 文献 · J Pediatr · 2018-04-03

该研究基于Sugar Babies随机试验数据,用决策树模型比较葡萄糖凝胶与标准治疗新生儿低血糖的总体成本。结果显示葡萄糖凝胶治疗每例婴儿节省NZ$1314.44,敏感性分析中仍保持成本节约,支持将葡萄糖凝胶作为新生儿低血糖的初始常规治疗。

要点

  • 葡萄糖凝胶治疗新生儿低血糖总体成本低于标准治疗,每例节省NZ$1314.44。
  • 敏感性分析显示在凝胶成本、NICU成本、剖宫产率和监测成本大幅变动下仍节省成本。
  • 葡萄糖凝胶无创、耐受好、安全且与改善母乳喂养相关,建议常规用于初始治疗。

核心结论

  • 使用颊部葡萄糖凝胶可降低新生儿低血糖的住院成本。
  • 葡萄糖凝胶无创、耐受好、安全且与改善母乳喂养相关,应常规用于新生儿低血糖的初始治疗。

研究设计与样本

  • 基于Sugar Babies随机对照试验数据的决策树模型,比较葡萄糖凝胶与安慰剂(标准治疗)的总体成本。
  • 成本包括低血糖监测与治疗特异性成本及婴儿在产后病房或新生儿重症监护室的住院时间相关成本。
  • 敏感性分析评估葡萄糖凝胶成本、新生儿重症监护成本、剖宫产率和血糖监测成本的影响。

主要发现

  • 主分析中葡萄糖凝胶治疗总体成本为NZ$6863.81,标准治疗(安慰剂)为NZ$8178.25,每例治疗婴儿节省NZ$1314.44。
  • 敏感性分析显示在葡萄糖凝胶成本、新生儿重症监护室成本、剖宫产率和监测成本大幅变化下,葡萄糖凝胶仍保持成本节约。

临床怎么用

  • 可将颊部葡萄糖凝胶作为新生儿低血糖的常规初始治疗,以降低住院成本。
  • 使用葡萄糖凝胶治疗新生儿低血糖时,需综合考虑监测、住院时间及NICU等相关成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the costs of using dextrose gel as a primary treatment for neonatal hypoglycemia in the first 48 hours after birth compared with standard care. STUDY DESIGN: We used a decision tree to model overall costs, including those specific to hypoglycemia monitoring and treatment and those related to the infant's length of stay in the postnatal ward or neonatal intensive care unit, comparing the use of dextrose gel for treatment of neonatal hypoglycemia with placebo, using data from the Sugar Babies randomized trial. Sensitivity analyses assessed the impact of dextrose gel cost, neonatal intensive care cost, cesarean delivery rate, and costs of glucose monitoring. RESULTS: In the primary analysis, treating neonatal hypoglycemia using dextrose gel had an overall cost of NZ$6863.81 and standard care (placebo) cost NZ$8178.25; a saving of NZ$1314.44 per infant treated. Sensitivity analyses showed that dextrose gel remained cost saving with wide variations in dextrose gel costs, neonatal intensive care unit costs, cesarean delivery rates, and costs of monitoring. CONCLUSIONS: Use of buccal dextrose gel reduces hospital costs for management of neonatal hypoglycemia. Because it is also noninvasive, well tolerated, safe, and associated with improved breastfeeding, buccal dextrose gel should be routinely used for initial treatment of neonatal hypoglycemia. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry: ACTRN12608000623392.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Glasgow MJ, Harding JE, Edlin R, et al. Cost Analysis of Treating Neonatal Hypoglycemia with Dextrose Gel. J Pediatr. 2018. PMID: 29625731. doi:10.1016/j.jpeds.2018.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。